Lung cancer drug trial halted: olaparib maintenance shows limited promise
NCT ID NCT02679963
First seen Apr 09, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tested whether the drug olaparib could help control advanced non-small cell lung cancer (NSCLC) after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, and results are not yet fully available. It involved 180 participants across France and Spain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy Cancer Campus
Villejuif, Val de Marne, 94805, France
Conditions
Explore the condition pages connected to this study.